MediciNova (NASDAQ:MNOV – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect MediciNova to post earnings of ($0.06) per share for the quarter.
MediciNova Price Performance
Shares of NASDAQ:MNOV opened at $1.96 on Wednesday. The company has a market capitalization of $96.13 million, a price-to-earnings ratio of -9.33 and a beta of 0.82. The firm’s 50 day simple moving average is $2.00 and its 200 day simple moving average is $1.83. MediciNova has a fifty-two week low of $1.12 and a fifty-two week high of $2.55.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. D. Boral Capital assumed coverage on shares of MediciNova in a research report on Monday, December 2nd. They issued a “buy” rating and a $9.00 price target on the stock. StockNews.com assumed coverage on shares of MediciNova in a research report on Tuesday, February 11th. They issued a “hold” rating on the stock.
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Further Reading
- Five stocks we like better than MediciNova
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- How to trade using analyst ratings
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.